There is no known cure for
rheumatoid arthritis. To date, the goal of treatment in rheumatoid
arthritis is to reduce joint inflammation and pain, maximize joint
function, and prevent joint destruction and deformity. Early
medical intervention has been shown to be important in improving
outcomes. Aggressive management can improve function, stop damage to
joints as monitored on X-rays, and prevent work disability. Optimal
treatment for the disease involves a combination of medications, rest,
joint-strengthening exercises, joint protection, and patient (and
family) education. Treatment is customized according to many factors
such as disease activity, types of joints involved, general health, age,
and patient occupation. Treatment is most successful when there is
close cooperation between the doctor, patient, and family members.
Two classes of medications are used in
treating rheumatoid arthritis: fast-acting "first-line drugs" and
slow-acting "second-line drugs" (also referred to as disease-modifying
antirheumatic drugs or DMARDs). The first-line drugs, such as aspirin
and cortisone (corticosteroids), are used to reduce pain and
inflammation. The slow-acting second-line drugs, such as gold, methotrexate (Rheumatrex, Trexall), and hydroxychloroquine (Plaquenil), promote disease remission and prevent progressive joint destruction, but they are not anti-inflammatory agents.
The degree of destructiveness of
rheumatoid arthritis varies among affected individuals. Those with
uncommon, less destructive forms of the disease or disease that has
quieted after years of activity ("burned out" rheumatoid arthritis) can
be managed with rest plus pain control and anti-inflammatory medications
alone. In general, however, function is improved and disability and
joint destruction are minimized when the condition is treated earlier
with second-line drugs (disease-modifying antirheumatic drugs), even
within months of the diagnosis. Most people require more aggressive
second-line drugs, such as methotrexate, in addition to
anti-inflammatory agents. Sometimes these second-line drugs are used in
combination. In some cases with severe joint deformity, surgery may be
necessary.